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The evolution of the cutaneous structure after topical treatment with P63 antiaging complex, assessed with high frequency
ultrasound,isstudiedbymeansofmulticriteriaoptimizationmodel.Duetothefactthattheimpactofthetreatmentmayinﬂuence
the quality of life, a medical index which measures, from this point of view, the eﬃcacy of the treatment is given, also taking into
account medical and economical aspects.
1.Introduction
The basic idea of Pharmaco-Economics studies is to gain a
physical and psychical comfort state for as long as possible,
with the smallest amount of money. Therefore, according to
these studies (see [1]) which consider a treatment in terms
of results related to costs, one of the following ﬁve types of
analysis is used: and cost-eﬀects (CEA), cost-minimization
(CMA), cost-utility (CUA), cost-eﬃciency (CEAC), and
cost-beneﬁt (CBA). Then, the data obtained after each of
this analysis are used to compare two or more treatments.
Cost-utility analysis was developed to help decision makers
compare the value of alternative interventions that have
very diﬀerent health beneﬁts, and it facilitates these com-
parisons without recourse to placing monetary values on
diﬀerent health states. The primary outcome of a cost-utility
analysis is the cost per quality-adjusted life years (QALYs)
or incremental cost-eﬀectiveness ratio (ICER), which is
calculated as the diﬀerence in the expected cost of two
interventions, divided by the diﬀerence in the expected
QALYs produced by the two interventions. QALYs measure
healthasacombinationofthedurationoflifeandthehealth-
relatedqualityoflife.Also,thereisanotherindex,denotedby
NB or INB, which means incremental net beneﬁt,d e ﬁ n e db y
INB = λΔe −Δc,( 1 )
where λ is the willingness to pay.
These indexes are largely used in the literature (see, e.g.,
[2–5]). Unfortunately, they may not always reﬂect with suﬃ-
cient accuracy all aspects of medical outcomes of treatment,
perception and impact of treatment on the patient’s psyche,
economic eﬀects, and so forth.
Using the multicriteria optimization technique, in [6]
a new index, called medicoeconomic index of a treatment
(denoted by MEI), is introduced. Its construction may use
all the desired aspects. It permits a simultaneous comparison
of two or more medical treatments. And, in addition, due to
thefactthatitemphasizestheimportanceofeveryaspectina
general context, it gains an increased ﬂexibility (see [7–10]).
Therearepapersintheliteraturewhichusemultifactorial
decisions to compare the medical treatments (see the book
[11] and the studies [12, 13]).2 Computational and Mathematical Methods in Medicine
The purpose of this paper is to show how the MEI index
may best quantify the eﬀect of applying a skin rejuvenation
treatment, taking into account multiple aspects: changes in
skin parameters occurred after treatment application, side
eﬀects, how the patient perceives the treatment and outcome
of application, cost of the treatment.
Quantiﬁcation, materialized by building the MEI index,
permits comparisons among several types of treatments or
comparing the results obtained with the same treatment
applied to diﬀerent groups of patients, groups that diﬀer
either by age or by phototype of the patients.
2. The Model on a SpeciﬁcSample
Let T be a medical treatment, applied against skin aging,
whoseeﬀect we want to quantify. In particular we considered
treatment with P63 antiaging complex.
From the treatment point of view, the patients were
classiﬁed in two groups of study: the ﬁrst group included
persons to whom the new medication to be tested was
applied, and the second group, the control group, to whom
the old medication was given. It is important to mention
t h a tb o t hg r o u p sw e r eh o m o g e n o u sr e l a t i v e l yt op a t i e n t
age, health state, and phenotype. From medical point of
view, the obtained results refer to thickness of the epidermis
(mm), thickness of the dermis (mm), number of low
echogenity pixels (LEP), medium and high echogenity pixels
(MEP and HEP), and the LEPs/LEPi ratio (low echogenic
pixels in the upper dermis/low echogenic pixels in the
lower dermis). All these imagistic parameters quantify both
the skin aging process and the eﬃcacy of the antiaging
treatments. For each of these parameters, the mean values
for every study group, age group, and phenotype group are
given.
Taking this into account, for each treatment Ti, i ∈
{1,2},e a c ha g eg r o u pj, j ∈{ 1,2,3},a n de a c hp h e n o t y p e
h, h ∈{ 2,3}, we indicate the following:
(i) Eijh1,Eijh2, the mean values of the thickness of
epidermis of the patients who take the treatment i,
are in age group j and have phenotype h,b e f o r e
the treatment, and, respectively, after the treat-
ment;
(ii) Dijh1,Dijh2, the mean values of the thickness of
dermis of the patients who take the treatment i,a r e
in age group j and have phototype h, before the
treatment, respectively, after the treatment;
(iii) Lijh1,Lijh2, the mean values of the LEP of the patients
who take the treatment i,a r ei na g eg r o u pj and have
phototype h, before the treatment, respectively after
the treatment;
(iv) Mijh1,Mijh2, the mean values of the MEP of the
patients who take the treatment i,a r ei na g eg r o u p
j and have phototype h, before the treatment,
respectively, after the treatment;
(v) Hijh1,Hijk2, the mean values of the HEP of the
patients who take the treatment i,a r ei na g eg r o u p
j and have phototype h, before the treatment,
respectively, after the treatment;
(vi) Fijh1,Fijk2, the mean values of LEPi/LEPu;
(vii) Rijh%, the percent of those with no adverse eﬀects
(erythema, pruritus, ocular disturbance, etc.);
(viii) Cijh, the mean value of the cost of treatment for the
period of time when the study was performed, taking
into account a person in group i,o fa g ej and a
phototype h.
The patients were asked to ﬁll in a questionnaire and give
two marks, denoted by q and s ∈{ 1,...,10}, concerning the
convenience of treatment application and the consequential
eﬀect of the treatment, respectively. We denote by Qijh and
Sijk, respectively, the mean values of the marks given by the
patients in age group j for the treatment i, and which have
phototype h.
Let K be the maximum accepted value for the cost of the
treatment for one patient during the study period of time.
2.1. Methods. The method used for comparison was that of
introducing a medicoeconomic index, by means of multicri-
teria optimization, which permits a rigorous observation of
the evolution of our patients.
For a protocol treatment Ti, the percentage Pijh%o f
patients from treatment group i,a g eg r o u pj, and phototype
h, is known.
Our problem was the following: having the previous
information and taking into account the cost of the new
treatment and the opinions of the patients, we wanted to
determine the eﬃcacy of the new treatment, and conse-
quently, if it was worth using it. The expected medical results
are increase of the mean thickness of epidermis and dermis,
decrease of the mean number of low echogenity pixels, the
increase of medium and high echogenity pixels, and the
increase of LEPs/LEPi ratio. From economical point of view,
it is desirable that the mean value of the cost for the new
treatment to be as low as possible.
Finally, from the patients’ point of view, the eﬀect of
the treatment is expected to be maximum possible and its
application as comfortable as it can be.
In order to solve this problem, we compared the
treatments at a general level (group 1 versus group 2 of
treatments), but also on each age group and phenotype
group. In every case, we had to solve a mathematical
multicriteria optimization problem.
We introduced the variables x1 and x2, which take only
the values 0 and 1. We have: x1 = 1, if the ﬁrst treatment
protocol is chosen, x1 = 0, if not; x2 = 1, if the second
treatment protocol is chosen, x2 = 0, if not. Due to the fact
that one patient has to follow one and only one treatment
protocol, we have the obvious condition x1 +x2 = 1.
Then we consider the functions: fk : {0,1}
2 −→ R, k ∈
{1,...,60},g i v e nf o re v e r yj ∈{ 1,2,3} and h ∈{ 2,3},
respectively, byComputational and Mathematical Methods in Medicine 3
f2(j−1)+(h−1)(x1,x2) = P1jh

E1jh2
E1jh1

x1 +P2jh

E2jh2
E2jh1

x2, ∀(x1,x2) ∈{ 0,1}
2,
f6+2(j−1)+(h−1)(x1,x2) = P1jh

D1jh2
D1jh1

x1 +P2jh

D2jh2
D2jh1

x2, ∀(x1,x2) ∈{ 0,1}
2,
f12+2(j−1)+(h−1)(x1,x2) = P1jh

L1jh1
L1jh2

x1 +P2jh

L2jh1
L2jh2

x2, ∀(x1,x2) ∈{ 0,1}
2,
f18+2(j−1)+(h−1)(x1,x2) = P1jh

M1jh2
M1jh1

x1 +P2jh

M2jh2
M2jh1

x2, ∀(x1,x2) ∈{ 0,1}
2,
f24+2(j−1)+(h−1)(x1,x2) = P1jh

H1jh2
H1jh1

x1 +P2jh

H2jh2
H2jh1

x2, ∀(x1,x2) ∈{ 0,1}
2,
f30+2(j−1)+(h−1)(x1,x2) = P1jh

F1jh2
F1jh1

x1 +P2jh

F2jh2
F2jh1

x2, ∀(x1,x2) ∈{ 0,1}
2,
f36+2(j−1)+(h−1)(x1,x2) =−

R1jh
P1jh

x1 −

R2jh2
P2jh

x2, ∀(x1,x2) ∈{ 0,1}
2,
f42+2(j−1)+(h−1)(x1,x2) = P1jh

Q1jh
10

x1 +P2jh

Q2jh
10

x2, ∀(x1,x2) ∈{ 0,1}
2,
f48+2(j−1)+(h−1)(x1,x2) = P1jh

S1jh
10

x1 +P2jh

S2jh
10

x2, ∀(x1,x2) ∈{ 0,1}
2,
f54+2(j−1)+(h−1)(x1,x2) =− P1jh

C1jh
K

x1 −P2jh

C2jh
K

x2, ∀(x1,x2) ∈{ 0,1}
2.
(2)
Obviously,ourpurposeistodetermine,simultaneously,their
maximum.Generally,thisfactcannotbefulﬁlled;therefore,a
compromised solution is to be accepted: a synthesis function
is considered and each of the previous functions gets a
weight, according to the importance of every criterion in the
problem.
So, ﬁrstly we attribute weights to the main elements of
our ﬁnal purpose:
(i) getting the best medical results (purpose indicated by
the functions f1,..., f36, f49,..., f54);
(ii) the best reception of the patient (functions f43,...,
f54);
(iii) thelowestpossiblecostofthetreatment(indicatedby
the functions f55,..., f60).
Eachofthesepurposesgetsanonnegativeweightdenoted
by tu (u ∈{ 1,2,3}), with the property that t1 + t2 + t3 = 1.
Obviously, the three weights may be or may be not equal.
Remark 1. In some other cases, we may distinguish these
weights even further. More precisely, the weight t2,c o r -
responding to the way in which the patient is contained
with the treatment may be considered as the sum between
two others weights: tQ, for the convenience of treatment
application and tS for the degree of content after the
treatment. Also, the weight t1 may be seen as the sum of
7 weights, tE,tD,tL,tM,tH,tF,tR, connected with the impor-
tance given to the increase of the thickness of the epidermis,
dermis, decreasing of low echogenity pixels, increasing of
medium and high echogenity pixels and increasing of ratio
LEPi/LEPu, respectively decreasing of the adverse reactions.
We change the notation of t3 with tC.
3. Comparing the Results at a GeneralLevel
and Constructing the MEI Index
In this case, the mathematical model of our medical problem
is the following multicriterial optimization problem with
the objective function F = (f1,..., f60):{0,1}
2 → R60,
previously given, and the set of possible solutions X =
{(x1,x2) ∈{ 0,1}
2 | x1 +x2 = 1}.
In order to solve this problem, we apply the weight
method and we construct the synthesis function Λ :
{0,1}
2 → R, Λ(x1,x2) =
60
i=1λi fi(x1,x2), for every x =
(x1,x2) ∈{ 0,1}
2,w h e r eλi is the importance (weight) given
to the criteria generated by function fi. Taking into account
thepreviousconsiderations,wesetλ1 =···=λ6 = tE, λ7 =
···=λ12 = tD, λ13 =···=λ18 = tL, λ19 =···=λ24 =
tM, λ25 = ··· = λ30 = tH, λ31 = ··· = λ36 = tF, λ37 =4 Computational and Mathematical Methods in Medicine
···=λ42 = tR, λ43 =···=λ48 = tQ, λ49 =···=λ54 =
tS, λ55 =···=λ60 = tC.
Any optimum solution of the problem
Λ(x1,x2) −→ max,

x 1 ,x2

∈ X (3)
is a max-eﬃcient point (max-Pareto point), so is acceptable.
Due to the fact that condition x1 + x2 = 1i m p l i e sx1 = 1 −
x2, the solving of problem (3) reduces to the solving of the
following problem:
ψ(u) =
60 
i=1
λi fi(u,1−u) −→ max, u ∈{ 0,1}. (4)
The simple form of the restrictions conduces immediately
to the conclusion: if ψ(1) >ψ (0), then u = 1 is the
optimal solution of problem (4); if not, u = 0 is the optimal
solution. This mathematical result permits us to introduce
theMEIindex,calledmedicoeconomicindex,attachedtothe
protocol Ti,b y
MEITi =
3 
j=1
2 
h=1

pijh

tE
Eijh2
Eijh1
+tD
Dijh2
Dijh1
+tL
Lijh2
Lijh1
+tM
Mijh2
Mijh1
+ tH
Hijh2
Hijh1
+tF
Fijh2
Fijh1

− tR
Rijk
pijk
	
+
3 
j=1
2 
h=1

pijh

tQ
Qijh2
Qijh1
+tS
Sijh2
Sijh1
−tC
Cijh
K
	
.
(5)
In case of small or homogenous samples, we may use the
easier formula:
MEITi =
3 
j=1
2 
h=1

tE
Eijh2
Eijh1
+tD
Dijh2
Dijh1
+tL
Lijh2
Lijh1
+ tM
Mijh2
Mijh1
+tH
Hijh2
Hijh1
+tF
Fijh2
Fijh1
−tRRijh

+
3 
j=1
2 
h=1

tQ
Qijh2
Qijh1
+tS
Sijh2
Sijh1
−tC
Cijh
K

.
(6)
Remark 2. Since for the construction of this index we
consider only data related to the patient’s condition before
and after treatment and data referring only this treatment,
the index can be used to compare several treatments, unlike
ICER and NB that allow comparison of only two treatments
and of only two criteria related to cost and eﬀectiveness.
4.SpecialCases
If we want to compare the overall eﬀectiveness of treatment
for two diﬀerent age groups, we may follow the same steps,
exceptthatweconsideronlythedatarelativetoanagegroup.
For example, if we want to compare the eﬃciency of the
treatment for each age group, i.e. 40–49, 50–59 and over 60,
we construct the MEI index by taking
MEIgrup j =
2 
h=1

P1jh

tE
E1jh2
E1jh1
+tD
D1jh2
D1jh1
+tL
L1jh2
L1jh1
+tM
M1jh2
M1jh1
+tH
H1jh2
H1jh1

− tR
R1jh
P1jh
	
+
2 
h=1

P1jh

tF
F1jh2
F1jh1
+tQ
Q1jh2
Q1jh1
+tS
S1jh2
S1jh1
−tC
C1jh
K
	
.
(7)
In case of small or homogenous samples, an easier formula
for computing the MEI index is the following:
MEIgrup j =
2 
h=1

tE
E1jh2
E1jh1
+tD
D1jh2
D1jh1
+tL
L1jh2
L1jh1
+tM
M1jh2
M1jh1
+tH
H1jh2
H1jh1
+tF
F1jh2
F1jh1
−tRR1jh

+
2 
h=1

tQ
Q1jh2
Q1jh1
+tS
S1jh2
S1jh1
−tC
C1jh
K

.
(8)
Another special case may be the one connected with the
phototype. In this case, we have
MEIphenotip h =
3 
j=1

P1jh

tE
E1jh2
E1jh1
+tD
D1jh2
D1jh1
+tL
L1jh2
L1jh1
+tM
M1jh2
M1jh1
+tH
H1jh2
H1jh1

− tR
R1jh
P1jh
	
+
3 
j=1

P1jh

tF
F1jh2
F1jh1
+tQ
Q1jh2
Q1jh1
+tS
S1jh2
S1jh1
−tC
C1jh
K
	
.
(9)
Or, the easier formula is as follows:
MEIphenotip h =
3 
j=1
tE
E1jh2
E1jh1
+tD
D1jh2
D1jh1
+tL
L1jh2
L1jh1
+tM
M1jh2
M1jh1
+tH
H1jh2
H1jh1
+tF
F1jh2
F1jh1
+tQ
Q1jh2
Q1jh1
+tS
S1jh2
S1jh1
−tC
C1jh
K
−trR1jk.
(10)
Also, if we want a result based both on the age group and
phototype, we have
MEIj,h = tE
E1jh2
E1jh1
+tD
D1jh2
D1jh1
+tL
L1jh2
L1jh1
+tM
M1jh2
M1jh1
+tH
H1jh2
H1jh1
+tF
F1jh2
F1jh1
tQ
Q1jh2
Q1jh1
+tS
S1jh2
S1jh1
−tC
C1jh2
K
−tRR1jh.
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Table 1: Group treated with P63 antiaging treatment.
Parameters Mean value
before treatment
Mean value after
treatment
Thickness of epidermis
(mm) 0.117 0.135
Thickness of dermis
(mm) 1.537 1.719
LEPs/LEPi 1.149 1.574
Table 2: Group treated with P63 complex, based on age groups.
Parameters Mean b.t.
40–49
Mean a.t.
40–49
Mean b.t.
50–59
Mean a.t.
50–59
Mean b.t.
60–75
Mean a.t.
60–75
Thickness of epidermis (mm) 0.114 0.135333 0.11675 0.1345 0.12025 0.136125
Thickness of dermis (mm) 1.8585 1.901 1.386313 1.740563 1.367625 1.506625
LEPs/LEPi 1.204593 1.457353 1.096062 1.398047 1.213842 1.510156
Table 3: Group treated with P63 antiaging treatment, based on phototype.
Parameters Mean b.t.
phototype 2
Mean a.t.
phototype 2
Mean b.t.
phototype 3
Mean a.t.
phototype 3
Thickness of epidermis (mm) 0.114625 0.129938 0.12 0.141
Thickness of dermis (mm) 1.605313 1.768063 1.460571 1.644214
LEPs/LEPi 1.198661 1.580802 1.092623 1.567998
5. Application of the P63 AntiagingTreatment
We exemplify the application of this index for the character-
ization of the treatment based on P63 antiaging treatment
(a metabolic dynamiser composed of alpha hydroxyacids,
retinoids, a biomimetic peptidic complex, and gluconolac-
toneincapsulatedinliposomes),intheparticularcaseofdata
presented in the following table and taken from [14]. Our
mathematical model was applied on a sample of 30 patients
with ages between 40 and 75 years old. Due to our purpose,
we divided them in three age interval groups: the ﬁrst
group included patients aged 40–50 years, the second group
included the aged ones 50–60, and the last group contained
those over 60. All patients included in the study belonged
to phototype class II or III, and, therefore, following this
criteria, we grouped them into two classes, denoted by 2
a n d3 .T h et r e a t m e n tc o s te q u a l s2 5 0m o n e t a r yu n i t s( m . u ) ;
the K constant is taken equal to 400. For those patients
who did not follow the treatment, the cost was considered
100m.u.
The medical data concerning the group treated with P63
antiaging treatment, as well as the placebo group, are given
in the following tables.
In order to compute the MEI index in case of P63
antiaging complex treatment, and placebo one, formula (6)
was used. It is important to mention that no side eﬀects were
noticed.
We considered equally the weights given for the age
groups. We take tE = 1/8,tD = 1/8,tF = 1/2,tR = tQ =
tS = 0, and tC = 1/4. Under these circumstances and using
the data from Table 1, the MEI index for the treatment with
Table 4: Placebo group.
Parameters
Mean value
before
treatment
Mean value
after treatment
Thickness of epidermis (mm) 0.1358 0.13505
Thickness of dermis (mm) 1.49635 1.57155
LEPs/LEPi 0.924757 1.042922
P63 antiaging complex was TP63 complex = 0.812143. Using
the data of Table 4 to build the MEI index for the placebo
treatment, we obtained T0 = 0.569481. This means that the
treatment is worth doing.
Using the same weights, the data from Table 2 and
denoting by “Mean” the mean value, b.t. = before treatment
and a.t. = after treatment and computing MEI for every
age group, we also got the following results: MEI40–49 =
0.724915, MEI50–59 = 0.897944, and MEI60–75 = 0.745013.
Thehighestvaluewasobtainedforthe50–59group,then
for the group 60–75 and then for 40–49 group. It means that
the age group 50–59 had the best response to the treatment.
Using the same weights, the data from Table 3 and
computing MEI, according with the formula for phototypes
2a n d3 ,w eg e tM E I 2 = 0.782524, respectively, MEI3 =
0.84888. The greatest value is obtained for phototype 3. This
result indicates that the treatment was best perceived for
phototype 3.
Remark 3. We mention that a change in the weights leads to
a change of the index.6 Computational and Mathematical Methods in Medicine
6. Conclusions
As mentioned before, starting with eﬀective data concerning
the treatment with P63 complex, we studied the possibility
to quantify the outcome of antiaging skin treatment, from
multiple points of view: medical parameters, side eﬀects,
cost, convenience of treatment application, the way in which
the patient perceive the treatment.
Using multicriteria optimization, we introduced a medi-
coeconomic index (MEI) capable to perform the required
quantiﬁcation. In its construction, only data connected with
a speciﬁc treatmentwereused; therefore,it hasthe advantage
of being able to compare more than 2 treatments.
Further, we gave an application in which we computed
the MEI index, in order to compare the P63 antiaging
complex treatment with a placebo one (which provided only
hydration of the skin). We also constructed speciﬁc indexes,
according to age groups. This permitted us to compare the
eﬀects of P63 complex treatment for diﬀerent age groups
and to establish, from this point of view, a hierarchy of these
groups.Thesameconstructionsandcomparisonsweremade
for the groups of phototypes 2 and 3.
The application presented documents the importance
and the facility of use of our index.
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